Lv6
2700 积分 2023-12-12 加入
[Evaluation considerations for using surrogate endpoints in anticancer clinical trials]
8天前
已完结
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management
8天前
已完结
成人恶性肿瘤高钙血症的治疗临床实践指南解读
9天前
已完结
Kidney disease in multiple myeloma
9天前
已完结
Renal Failure in Multiple Myeloma
9天前
已关闭
Emergency Medicine Clinics Hypercalcemia/Multiple Myeloma
9天前
已完结
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
10天前
已完结
Treatment Decisions in Multiple Myeloma
15天前
已完结
Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma
15天前
已完结
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
15天前
已完结
皖公网安备34019202002308
